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ABSTRACT
Tumor-associated neo-antigens are mutated peptides that allow the immune system to recognize the
affected cell as foreign. Cells carrying excessive mutation load often develop mechanisms of tolerance.
PD-L1/PD-1 checkpoint immunotherapy is a highly promising approach to overcome these protective
signals and induce tumor shrinkage. Yet, the nature of the neo-antigens driving those beneficial
responses remains unclear. Here, we show that APOBEC-related mutagenesis – a mechanism at the
crossroads between anti-viral immunity and endogenous nucleic acid editing – increases neo-peptide
hydrophobicity (a feature of immunogenicity), as demonstrated by in silico computation and in the
TCGA pan-cancer cohort, where APOBEC-related mutagenesis was also strongly associated with immune
marker expression. Moreover, APOBEC-related mutagenesis correlated with immunotherapy response in
a cohort of 99 patients with diverse cancers, and this correlation was independent of the tumor
mutation burden (TMB). Combining APOBEC-related mutagenesis estimate and TMB resulted in greater
predictive ability than either parameter alone. Based on these results, further investigation of APOBEC-
related mutagenesis as a marker of response to anti-cancer checkpoint blockade is warranted.
ARTICLE HISTORY
Received 5 June 2018
Revised 11 October 2018
Accepted 10 November 2018
KEYWORDS
Mutagenesis; APOBEC; neo-
epitopes; immunotherapy;
cancer
Antigen presentation is the process by which endogenous and/or
exogenous protein fragments are presented to the immune sys-
tem in the form of short peptides associated with antigen-
presenting molecules. There are two types of antigen-
presenting molecules: (i) major histocompatibility complex
(MHC) class I molecules displaying peptides of 8–10 residues
(derived from intracellular proteins) to CD8+ cytotoxic T-cells;
and (ii) MHC class II molecules found on antigen-presenting
cells displaying peptides of 18–20 residues (derived from extra-
cellular proteins) to CD4+ helper T-cells.1 If the cells are healthy,
only ‘self’ peptides will be displayed and will be greeted by
immunological tolerance; if the cells have been infected by
pathogens, ‘non-self’ peptides will appear and activate the anti-
gen-specific immune response.
A similar mechanism should be observed with tumor cells
harboring somatic mutations. The higher the number of geno-
mic alterations, the more likely that the mutated cells will pro-
duce a set of proteins different from non-mutated cells and
capable of triggering immune activation. Interestingly, these
highly-mutated tumors often express immune checkpoints
such as programmed cell death 1 (PD-1) ligands, acting as
inhibitory signals for the immune response.2 In such tumors,
immune checkpoint expression is induced by IFN-γ produced
within the inflammatory microenvironment,3 leading to the
death of tumor-specific T-lymphocytes despite an initial immu-
nogenic neo-antigen exposure. Several immunotherapeutic
agents (e.g. anti-PD-1/PD-L1 antibodies) have been developed
in order to ‘break’ this tolerance mechanism. These agents have
shown high efficacy in malignancies with high tumor mutation
burden (TMB), such as melanoma and subsets of patients with
non-small cell lung carcinomas (NSCLC).4–9 High response
rates have specifically been associated with tumor PD-1 ligand
1 (PD-L1) over-expression 4,6,7 and mismatch-repair
deficiency;6,10 the latter virtually always presenting a high
TMB. PD-L1 overexpression has been linked to specific muta-
genic mechanisms, such as DNA polymerase δ or ε (POLD1/
POLE) deficiency and apolipoprotein BmRNA-editing cytidine-
deaminase (APOBEC) hyper-activity.6,11,12 The APOBEC family
is of particular interest in this context: these evolutionarily con-
served enzymes act as protective factors against viral infections,
by inducing mutation altering viral replication. However,
APOBEC off-target genotoxic effects result in alterations of the
host genome and thus, are also implicated in tumor hyper-
mutation processes.13
It is plausible that highly-mutated, immunogenic tumors
require PD-L1 overexpression (or other alterations resulting in
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immune tolerance) in order to survive and be observed.12 Our
previous data have shown that APOBEC overexpression or
APOBEC-related mutagenesis (also referred to as kataegis,
a phenomenon of localized hyper-mutation primarily described
in breast cancer14 and later attributed to AID/APOBEC enzyme
hyper-activity15) are independently correlated with high PD-L1
expression. Further, if both APOBEC expression (or APOBEC-
related mutagenesis) and TMB are included in the multivariate
model, TMB is no longer an independent correlate of PD-L1
overexpression, suggesting that certain mutational processes,
such as those related to APOBEC, are most relevant to trigger
the PD-L1 immune shielding12.
One could hypothesize that precise mutational processes
result in specific neo-antigen physicochemical properties. In
this study, we aimed to describe the molecular consequences of
APOBEC hyper-activity on peptides subsequently created, and
found that APOBEC-related mutagenesis increases neo-peptide
hydrophobicity. There is considerable literature suggesting that
hydrophobicity is a feature of peptide antigenicity and
immunogenicity.16-18 Accordingly, we showed that APOBEC-
related mutagenesis associates with immune marker expression
in human tumor samples and correlates with immunotherapy
response in pan-cancer patients. The results presented herein
suggest the use of APOBEC-related mutational signature as
a biomarker of response to immunotherapy by checkpoint
blockade in cancer patients.
Results
Hydrophobicity of the human coding genome increases
after in silico apobec-related mutagenesis
All existing unique 6-nucleotide stretches (n = 4,096 – each of
the positions within the 6-nucleotide stretches can be occu-
pied by one of the four different natural nucleotides A, T, C,
G and therefore, the number of 6-nucleotide stretches is equal
to 46) were used as a template for in silico mutagenesis
analysis. Virtual single-nucleotide substitutions corresponding
to the description of AID/APOBEC mutagenesis pattern (i.e.
the average of mutation signatures ‘2ʹ and ‘13ʹ, as previously
described 19) was applied on this set of 4,096 virtual stretches.
The 2nd, 3rd, 4th or 5th nucleotide of each stretch could be
mutated, resulting in a total of 49,152 possible changes (4,096
stretches possibly mutated in four positions, by three different
nucleotide substitutions). The sum of hydropathic indices
corresponding to the dipeptides encoded by the virtual
stretches was then weighted by the probability of observation
of said-stretch in the genome (i.e. taking into account the
nucleotide-content and codon-usage variability inherent to
the coding genome) and by the probability to observe
a mutation within the stretch (as described by ref.19).
Hydropathic indices were then compared before and after
single-round of in silico mutagenesis.
Application of the in silico computational method resulted
in a significant difference in hydrophobicity ranks when con-
sidering stretches presenting at least one APOBEC-related
mutation pattern (at the nucleotide level) (N = 3,744; 91.4%
of all existing stretches) or when considering all 4,096 possible
stretches (sum of sign ranks W = 2.8x106; p-value < 0.0001)
(Table 1). The median hydrophobicity change per stretch was
positive for both analyses (+2.9x10−8 and +1.0x10−7 arbitrary
unit (AU)), and the sum of hydrophobicity changes for all
stretches – corresponding to the hydrophobicity change
caused by a single APOBEC-related mutation in the human
coding genome – was equal to +0.0235 AU (Table 1).
Reciprocal alterations were not included in this analysis
because of a previously reported bias against mutations in
the reciprocal strand.19 However, the analysis considering
reciprocals mutations (e.g. TCT→TTT and AGA→AAA)
showed similar results, with a median hydrophobicity change
per stretch of +1.8x10−7 AU and a hydrophobicity change of
the coding genome of +0.0163 AU (Supplemental Table 1).
Therefore, our in silico computation showed that APOBEC-
related mutagenesis induces an imbalance in favor of hydro-
phobic dipeptides in the human coding genome.
The in silico computation described above was also per-
formed on 5-nucleotide stretches rather than 6-nucleotides
stretches, simulating substitutions on the 2nd, 3rd, and 4th
nucleotides. This computation led to similar conclusions (data
not shown).
Repeated APOBEC-related mutagenesis amplifies the
hydrophobicity change
We further evaluated the impact of repeated in silico
APOBEC-related mutagenesis over the estimated overall
hydrophobicity of the coding genome (the mutated stretches
being used as a template for additional rounds of mutagen-
esis). The reference coding genome (baseline) tends to be
hydrophilic, with a score of −0.3592 AU (calculated by sum-
ming the hydropathic indexes weighted by the probability of
observation of all stretches). After 100 rounds of APOBEC-
related mutagenesis, the overall hydrophobicity was estimated
at −0.0937 AU, corresponding to a +73.9% increase from the
baseline (Figure 1A). Interestingly, a noticeable increase in
hydrophobicity was also seen after ultra-violet (UV) in silico
mutagenesis (+160%), but not with other mutagenesis pro-
cesses such as mismatch repair, BRCA1/2 and polymerase
deficiencies or tobacco-smoked exposure (using mutation sig-
natures previously described by ref. 19) (Figure 1A).
We then aimed to describe the modification in dipeptide
amino-acid content after APOBEC-related mutagenesis. The
application of our in silico computation revealed the appari-
tion of specific hydrophobic residues, to the detriment of
more hydrophilic residues, after both single and repeated
APOBEC-related mutagenesis (Figure 1B-C). Particularly, an
increase of +15/+69% (after one or 20 APOBEC-related muta-
genesis iteration, respectively) was observed for cysteine resi-
dues (hydropathic index = +2.5 AU) and +6/+28% for
phenylalanine (+2.8 AU), whereas serine (−0.8 AU) was the
amino acid most commonly lost (−15/-53%) (Figure 1D).
Additionally, we noticed an important increase in the number
of stop-codons (+116/+364%) (Figure 1E).
Taken together, we demonstrated that the APOBEC-
related mutagenesis process induces a significant modification
of the coding genome template, possibly resulting in an
increase of synthesis of hydrophobic residues by the muta-
genic tumor cell.
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APOBEC-related mutagenesis-positive tumors show an
increase in peptide hydrophobicity
A subset of 469 highly-mutated tumor samples (top 30% tumors
in term of mutation burden, exempt from mismatch repair or
DNA polymerases deficiencies) was selected from The Cancer
Genome Atlas (TCGA) database. These tumors presented an
average of 335 mutations (95% confidence interval CI95%
= 302–368 alterations) and 230 of them presented at least one
APOBEC-related mutagenesis pattern. APOBEC-related muta-
genesis-positive tumors carried an average of 84 APOBEC-
related substitutions per tumor (CI95% = 67–101 substitutions).
An analysis considering full-length mutated transcripts was
first performed: 93,465 different transcripts corresponding to
15,163 unique genes were reviewed. The difference in hydro-
phobicity evaluated for each transcript before and after muta-
genesis was summed by tumor. Highly-mutated tumors
presenting alterations possibly caused by APOBEC (as evalu-
ated by P-MACD results) showed a significant increase in
hydrophobicity change of their transcriptome/proteome in
comparison to tumors not altered by APOBEC (+6,775 AU
versus +2,759 AU; p-value < 0.0001) and this difference
remained significant when the hydrophobicity change was
weighted by the expression level of each transcript (+11x108
AU versus +3.5x108 AU; p-value < 0.0001) (Supplemental
Table 2). Similar results were found for tumors presenting
an intermediate or low TMB (Supplemental Table 2).
Another analysis consisted in the generation of presentable
8- to 10-mer neo-peptides: 2,660,232 neo-peptides (all possi-
ble 8- to 10-mer peptides encompassing the mutations
observed in the tumors of interest) were generated. Table 2
shows a significant increase in overall hydrophobicity for
tumors positive for APOBEC-related mutagenesis compared
to those without APOBEC-related alterations (+8,702 AU
versus +3,374 AU; p-value < 0.0001), The significant differ-
ences are maintained when the change in total hydrophobicity
is weighted by neo-peptide expression level (+22.2x108 AU
versus +2.6x108 AU; p-value < 0.0001), and this held true
when examining the entire group of tumors, as well as for
tumors in the lower 70% TMB (Table 2).
Tumor neo-peptide hydrophobicity correlates with the
number of APOBEC-related mutations
For highly-mutated TCGA tumors presenting an
APOBEC-related mutation signature (N = 230), the overall
hydrophobicity change was significantly and positively
correlated to the number of mutations specifically caused
by APOBEC (R2 = 0.27; p-value < 0.0001). Of interest, this
correlation revealed two distinct groups of tumors:
a group composed of melanomas (N = 52; R2 = 0.90;
p-value < 0.0001) and a group of tumors with diagnoses
other than melanoma, that disclosed a lower regression
slope than that of the melanoma group (N = 178;
R2 = 0.70; p-value < 0.0001) (Figure 2A). These results
mirrored those calculated by our in silico computation
observed above (Figure 1A); the latter demonstrated that
both UV-related (the hallmark of melanoma) and
APOBEC-related mutagenesis processes specifically cause
an increase in overall coding genome hydrophobicity.
Further analysis showed that, in highly-mutated tumors, the
change in hydrophobicity for 8- to 10-mer peptides (i.e. the sum
of hydrophobicity of all 8- to 10-mer neo-peptides generated per
tumor) was significantly higher in APOBEC-related-mutagenesis
-positive versus APOBEC-related-mutagenesis-negative tumors,
regardless of whether these tumors were diagnosed as non-
melanoma or melanoma (p-value < 0.001) (Figure 2B-C).
Table 1. Consequences of a single iteration of APOBEC-related mutagenesis on the overall hydrophobicity of the human coding genome (per in silico computation)a
A. CONSIDERING ALL STRETCHES B. CONSIDERING ONLY MUTATED STRETCHESb
Hydrophobicity (AU)c Hydrophobicity (AU)
Before
mutagenesis
After
mutagenesis Difference Before mutagenesis
After
mutagenesis Difference
Number of stretches 4096 3744
Median −0.00003438 −0.00003418 + 2.9 x 10−8 0 −0.000003384 + 1.0 x 10−7
25% percentile −0.0006361 −0.0006178 −1.0 x 10−7 −0.000486 −0.0004733 −1.3 x 10−7
75% percentile 0.0003892 0.000396 1.0 x 10−6 0.0004366 0.000448 1.3 x 10−6
Mean −0.0001756 −0.0001698 + 5.7 x 10−6 −0.000009969 −0.000003683 + 6.3 x 10−6
Standard deviation 0.001392 0.00139 2.1 x 10−5 0.001202 0.001199 2.2 x 10−5
Standard error 0.00002175 0.00002172 3.2 x 10−7 0.00001964 0.00001959 3.5 x 10−7
Lower 95% CI −0.0002182 −0.0002124 5.1 x 10−6 −0.00004847 −0.00004209 5.6 x 10−6
Upper 95% CI −0.0001329 −0.0001272 6.4 x 10−6 0.00002853 0.00003472 7.0 x 10−6
Sum −0.7191 −0.6955 + 0.0235 −0.03732 −0.01379 + 0.0235
Wilcoxon signed rank test
Sum of signed ranks (W) 2.79 x 106 2.79 x 106
P-value < 0.0001 < 0.0001
Abbreviations: AU = arbitrary unit; CI = confidence interval.
aAPOBEC-related mutagenesis patterns 2 and 13 (as described by ref.19) were used. Table 1A shows the result of the analysis using all existing 6-nucleotides
stretches (mutated or not), whereas Table 1B shows the result of the analysis using only 6-nucleotides stretches presenting a mutation. Alterations on the
reciprocal strands were not included because of an existing bias against mutations in the reciprocal strand19. See Supplemental Table 1 for calculations with the
use of the reciprocal strand.
bMutated stretches are nucleotide stretches presenting a different nucleotide sequence after application of the mutagenesis pattern.
cThe overall hydrophobicity of the coding genome was obtained by summing the hydropathic indices of all existing codons (using the hydrophobicity scale described
by ref.34), weighted by their frequency of observation (using the codon usage described by ref.37).
ONCOIMMUNOLOGY e1550341-3
Figure 1. Amino-acid distribution and relative hydrophobicity of the human coding genome after 1 and 20 APOBEC-related iterations (by in silico computation), as
compared as other causes of mutagenesis.
Panel A shows changes in human coding genome overall hydrophobicity after multiple iterations of APOBEC-related mutagenesis, as computed in silico (n = 1 to
100 iterations). All nucleotides stretches (mutated or not) were included, reciprocals were not considered. Results obtained by applying the same method to
alternative mutation signatures are shown for comparison purposes.Panel B and C show changes in hydrophobicity distribution after a single (B) or multiple (C)
APOBEC-related mutagenesis iteration of all 6-nucleotide stretches whether or not they would be expected to be mutated; reciprocals wre not included. The figure
breaks down the changes by hydrophobicity categories. There is a loss of hydrophilic amino acids (left side of the mountain graphic) and a gain of hydrophobic
amino acids (right side of the mountain graphic).Panel D and E show the percentage of change of each amino acid (D) and codon stop (E) after 1 and 20 iterations
of APOBEC-related mutagenesis.Amino-acid code – alanine (Ala, A), arginine (Arg, R), asparagine (Asn, N), aspartic acid (Asp, D), cysteine (Cys, C), glutamic acid (Glu,
E), glutamine (Gln, Q), glycine (Gly, G), histidine (His, H), isoleucine (Ile, I), leucine (Leu, L), lysine (Lys, K), methionine (Met, M), phenylalanine (Phe, F), proline (Pro, P),
serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), tyrosine (Tyr, Y), valine (Val, V), stop codon (X, *).
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Similar results were seen for non-melanoma tumors when the
hydrophobicity score was weighted by the corresponding expres-
sion level (p-value < 0.0001) (Figure 2D), but not for melanoma
perhaps because of the small number of melanomas exempt of
APOBEC-related mutagenesis (N = 9; p-value = 0.206)
(Figure 2E).
The following analyses were performed in non-melanoma
tumors exclusively, in order to avoid possible spurious asso-
ciations due to the UV-related mutagenesis confounder factor.
APOBEC-related mutagenesis is associated with immune
cell marker expression
The presence of an APOBEC-related mutagenesis pattern in
non-melanoma malignancies was associated with the overex-
pression of PD-L1/2 ligands (odds ratio (OR) = 1.9;
p-value = 0.006). The overexpression of IFNγ, a marker of
lymphocyte activation, and the overexpression of T-cell specific
markers, such as CD4 (associated with the presence of CD4+
helper T-cells) and CD8A (associated with the presence of CD8+
cytotoxic T-cells), were also significantly associated with the
presence of APOBEC-related mutagenesis in the cohort of non-
melanoma tumors (OR > 2.85; p-value < 0.0001) (Supplemental
Table 3).We have previously shown that lymphocyte infiltration
is independently associated with both TMB and APOBEC
mutagenesis.12
APOBEC-related mutagenesis is associated with
immunotherapy response in cancer patients
We analyzed a cohort of 99 non-melanoma patients pre-
viously treated by immunotherapy at the UCSD Moores
Cancer Center, Center for Personalized Cancer Therapy.
Mutation assessment was performed by next-generation
sequencing using a 315-gene panel (FoundationOne® assay,
Foundation Medicine Inc.).
First, we evaluated if results from panel-based assays could
be used as a surrogate for whole-exome APOBEC-related
mutational signature enrichment (AMSE) score. Using the
TCGA pan-cancer cohort, the correlation between the results
obtained by using all exome regions versus these obtained
using only the regions covered by the commercial panel was
estimated at R2 = 0.7225 and was considered significant
(p-value < 0.0001) (Supplemental Figure 1).
The threshold segregating patients between levels of
APOBEC-related mutagenesis was determined using the
Receiver Operating Curve (ROC) method. An AMSE score
threshold of 0.727 permitted discrimination between patients
Table 2. Comparison of change in hydrophobicity of the neo-peptide library (8- to 10-mer peptides) of TCGA tumors (whole exome sequencing) with and without
APOBEC-related mutagenesisa.
TOP 30% OF TUMORS BY MUTATION BURDEN
APOBEC-mutagenesis NEGATIVE
(n = 239)
APOBEC-mutagenesis POSITIVE
(n = 230) p-value
Change in hydrophobicity, by tumorb
Mean [CI, 95%] (AU) + 3,374 [2,987–3,761] + 8,702 [7,506–9,898] < 0.0001
Median [range] (AU) + 2,763 [−1,692–22,428] + 5,587 [765–70,444]
Expression-weighted change in hydrophobicity, by tumorf
Mean [CI, 95%] (AU) + 2.6 [−8.9–14.2] x108 + 22.2 [17.7–26.6] x108 < 0.0001
Median [range] (AU) + 5.1 [−1,344–215] x108 + 11.5 [−63–291] x108
LOW 70% OF TUMORS BY MUTATION BURDEN
APOBEC-mutagenesis NEGATIVE
(n = 2,859)
APOBEC-mutagenesis POSITIVE
(n = 156)
p-value
Change in hydrophobicity, by tumor
Mean [CI, 95%] (AU) + 563 [538–588] + 1,172 [1,042–1,301] < 0.0001
Median [range] (AU) + 417 [−2,550–4,032] + 1,075 [−617–3,260]
Expression-weighted change in hydrophobicity, by tumor
Mean [CI, 95%] (AU) + 2.5 [0.9–4.1] x 108 + 6.6 [1.9–11] x 108 < 0.0001
Median [range] (AU) + 0.4 [−410–2,000] x 108 + 1.6 [−44–296]] x 108
ALL TUMORS
APOBEC-mutagenesis NEGATIVE
(n = 3,098)
APOBEC-mutagenesis POSITIVE
(n = 386)
p-value
Change in hydrophobicity, by tumor
Mean [CI, 95%] (AU) + 780 [734–826] + 5,659 [4,856–6,462] < 0.0001
Median [range] (AU) + 473 [−2,550–22,428] + 2,802 [−617–70,444]
Expression-weighted change in hydrophobicity, by tumor
Mean [CI, 95%] (AU) + 2.5 [0.8–4.2] x 108 + 16 [13–19] x 108 < 0.0001
Median [range] (AU) + 0.5 [−1300–200] x 108 + 6.1 [−63–296] x 108
Abbreviations: AU = arbitrary unit; CI = confidence interval.
a An analysis of hydrophobicity was performed on a set of highly mutated pan-cancer tumors (top 30% of mutational load in TCGA), not presenting mismatch repair
or polymerases delta and epsilon alterations, classified as APOBEC-related mutagenesis positive or negative using the P-MACD estimates provided by the Broad
GDAC Firehose website (https://gdac.broadinstitute.org). The lower 70% of tumors by mutational burden was analyzed as well. See Supplemental Table 2 for data
obtained for full-length transcripts.
b The change in hydrophobicity induced by the mutagenesis on all possible 8- to 10-mer neo-peptides of a tumor is shown. The peptide hydrophobicity was
evaluated before and after mutagenesis, by summing residue hydrophobicity indices. The hydrophobicity change induced by the mutagenesis was calculated for
each peptide, and these changes were then summed by tumor.
c The expression-weighted change in hydrophobicity was calculated in a manner identical as described above, except that each hydrophobicity score was multiplied
by the corresponding level of transcript expression.
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with or without response to immunotherapy with a sensitivity
of 95% (18/19 patients that responded to immunotherapy had
high AMSE score) and a specificity of 35% (28/80 patients
who did not respond to immunotherapy had low AMSE
score). Using this threshold, AMSE score has a negative pre-
dictive value of 97% and a positive predictive value of 26%.
In the cohort of 99 patients having received immunother-
apy, demographic and molecular features significantly asso-
ciated with a high AMSE score were the gender (men are
more likely to present an ‘APOBEC-high’ phenotype;
p-value = 0.0032) and the presence of an intermediate or
high TMB (p-value = 0.0187 and 0.0060, respectively).
Patients with a high AMSE score were more likely to have
a complete (CR) or partial (PR) response (OR = 9.69;
p-value = 0.0106) and presented a median PFS of 3.1 months,
while those with low AMSE score had a median PFS of
2.1 months (Hazard Ratio (HR) = 0.60; p-value = 0.0239)
(Supplemental Table 4 and Figure 3).
In univariate analysis, the factors positively associated with
a response to immunotherapy were high TMB and high
APOBEC/AMSE score (p-value = 0.0027 and 0.0106, respec-
tively), whereas a low TMB was negatively associated with the
Figure 2. Overall change in hydrophobicity in human tumors positive for APOBEC-related mutagenesis.
Panel A. Correlation between the overall neo-peptide hydrophobicity change and the total number of APOBEC-related mutations in highly-mutated human tumors
positive for APOBEC-related mutagenesis.Panels B-E. Comparison of neo-peptide hydrophobicity change in highly mutated tumors with or without APOBEC-related
mutagenesis, in different subgroups of tumors (non-melanoma (B, D) and melanoma tumors (C, E)), considering the hydrophobicity scores before (B, C) or after (D,
E) weighting by the mRNA-expression levels. Mean and 95% confidence intervals are represented in bold bars.
e1550341-6 A. BOICHARD ET AL.
response (p-value = 0.0006). In multivariate analysis, the only
factor remaining independently and positively associated with
the outcome was the APOBEC/AMSE score (OR = 10.99;
p-value = 0.031) (Table 3, Supplemental Table 5 and
Supplemental Table 6).
In addition, we also generated exploratory empirical prob-
abilistic models combining TMB and APOBEC/AMSE score
to predict clinical response to immunotherapy. These models
allow us to estimate the complementarity of TMB (an estab-
lished biomarker of response to immunotherapy20,21) and
APOBEC-related mutagenesis process, assuming that these
criteria are either 1/independent or 2/dependent and partially
sharing common information, without discretization, thresh-
olding or other simplifying assumptions. As can be seen in the
ROC curves presented in Supplemental Figure 2A-B, the
model with the highest area under the curve (AUC) corre-
sponds to the one that combines TMB and APOBEC/AMSE
score (AUC = 0.892 and AUC = 0.862 with or without
common polymorphisms filtering, respectively). This model
shows significant model-fit (p-value < 0.0001). When TMB
and APOBEC/AMSE score are considered together, the opti-
mized sensitivity and specificity are about 90% and 65%
(Supplemental Figure 2A-B). To note, further predictive
power would have to be evaluated using an independent set.
Discussion
Immunotherapy uses the innate immune system’s ability to
detect and fight abnormal cells (such as ‘non-self’, infected, or
tumor cells) in order to treat cancer. Recent successes of
exceptional responses to PD-1/PD-L1 blockade in melanoma,
NSCLC, and Hodgkin lymphoma, have led to an exponential
interest in this matter.5,22,23 Interestingly, while immunother-
apy may lead to complete responses in certain types of cancer,
other tumors seem resistant to checkpoint blockade agents,
with overall response of 19% in unselected populations.7 The
causes for such dichotomous results are still unclear, and
biomarkers allowing an early stratification of patients suscep-
tible to benefit from such agents are needed.24 It appears that
microsatellite instability (MSI)-high tumors present high
Figure 3. Response and progression-free survival comparison between patients treated with checkpoint blockade presenting differential APOBEC-related mutagen-
esis phenotypes.
An estimate of the APOBEC-related mutagenesis was obtained for each patient using the AMSE tool. Patients were classified in low APOBEC-related mutagenesis
phenotype for scores ≤ 0.727 and in high APOBEC-related mutagenesis phenotype for scores > 0.727. Panels A: Pie-charts of response in patients presenting a low
versus high APOBEC-related mutagenesis score. Panel B: Kaplan-Meier curve for progression-free survival of patients with APOBEC-related mutagenesis score low
versus high.Abbreviations: CI = confidence interval; HR = hazard ratio; OR = odds ratio.
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response rates to pembrolizumab, explaining its recent
approval by the Food and Drug Administration (FDA)
regardless of tumor type.10,25,26 Patients whose tumor exhibits
PD-L1 expression by immunohistochemistry.4–6 or PD-L1
amplification by sequencing 27 achieve higher response rates
to blockade than patients without these features. However,
some patients who do not express PD-L1 can still have
impressive responses to PD-1 blockade. Lastly, virally-
induced tumors such as Merkel cell carcinoma also responds
well to checkpoint blockade.28
PD-L1 overexpression itself has been linked to high TMB,
polymerases δ (POLD1) and ε (POLE) alterations and, more
recently, to APOBEC cytidine-deaminases hyper-activity.6,11,12
It is plausible that highly mutated or immunogenic tumors
require PD-L1 overexpression (or other alterations that result
in immune tolerance) in order to survive.12 Interestingly, our
previous data 12 have shown that, in multivariate analysis,
APOBEC overexpression or APOBEC-related mutagenesis pat-
tern are independently correlated with high PD-1 ligand expres-
sion. Further, if both APOBEC–related signature and TMB are
included in the multivariate analysis, TMB is no longer selected
as an independent correlate of PD-1 ligand overexpression,
suggesting that only certain hyper-mutated subtypes elicit the
immune shielding that PD-L1 or PD-L2 provides.
In this study, we found that the mutational signatures speci-
fically caused by APOBEC enzymes (often in response to virus
infection) 29 significantly increase the overall hydrophobicity of
the human coding genome, as shown by in silico computation
and by examining pan-cancer TCGA sequencing data. The
increased APOBEC-associated hydrophobicity was seen regard-
less of the TMB. Importantly, the overall change in hydropho-
bicity of putative neo-antigens presented was proportionally
correlated to the number of APOBEC-related mutations, as
assessed by both computation method or observed from
TCGA data. This escalation in hydrophobicity indices is relevant
because T-cells preferentially recognize antigens containing
hydrophobic residues.17 It is also known that the binding affinity
of 8- to 10-mer peptides to MHC class I proteins (which present
antigens to T-cells) is largely determined by the anchor amino
acids allowing the interaction with the MHC hypervariable
region,16 and these anchor residues also tend to be
hydrophobic.16 Therefore, it appears that peptide hydrophobi-
city is a mandated physicochemical feature eliciting both anti-
genicity and immunogenicity 18 and we hypothesized that, by
modifying the peptide physicochemical feature, APOBEC
hyper-activity may, at least indirectly, play a role in the tumor
immune response. Indeed, a recent study reports a positive
correlation between APOBEC3B upregulation, i.e. enrichment
in the APOBEC mutation signature, and known immunother-
apy response biomarkers such as PD-L1 expression and T-cell
infiltrates in non-small cell lung carcinoma.30 Interestingly, UV-
related mutation signature also seems to promote an increase in
hydrophobic 8- to 10-mer peptides, as assessed by bothmethods,
and this may be consistent with the high response rates to
checkpoint blockade observed in melanoma patients.31 The
implication of APOBEC hyper-activity in the tumor immune
response may also be suspected, because in the TCGA pan-
cancer cohort, the presence of APOBEC-related mutagenesis
was significantly associated with the expression of IFNγ and
T-cell specific markers CD4 and CD8A. These cytokine and
lymphocyte markers are known to be associated with lympho-
cyte activation and response to checkpoint blockade.32 It is
important to note that other well-known mutagenic processes,
such as mismatch repair, BRCA1/2 or polymerase deficiency
mutation patterns, however, do not seem to increase the neo-
peptide hydrophobicity.
Table 3. Factors affecting the outcome of patients treated with immunotherapy agents.
Complete or partial
response
N (%)
Stable or progressive
disease
N (%)
P – value
univariateg
P-value
multivariateh OR [95% CI]i
Tumor type NSCLCj 7 (19%) 29 (81%) > 0.9999
Other tumorsk 12 (19%) 51 (81%)
TMBl Low 2 (4%) 44 (96%) 0.0006 0.006 0.09 (0.017–0.51)
Intermediate 8 (24%) 25 (76%) 0.4211
High 9 (45%) 11 (55%) 0.0027 0.651 1.34 (0.37–4.85)
APOBEC-related
mutagenesism
Low 1 (3%) 28 (97%) 0.0106 0.031 10.99 (1.25–100)
High 18 (26%) 52 (74%)
Type of immunotherapy Anti-PD-1/PD-L1
monotherapy
16 (18%) 75 (82%) 0.1780
Other immunotherapyn 3 (38%) 5 (62%)
Abbreviations: CI = confidence interval; CTLA4 = cytotoxic T-lymphocyte associated protein 4; Mb = megabase; N = number; NSCLC = non-small cell lung cancer;
OR = odds ratio; PD-1 = programmed death receptor-1; PD-L1 programmed death receptor-ligand 1; PFS = progression free survival; TMB = tumor mutational
burden.
a Calculated using Fisher’s exact test. Supplemental Table 4 shows the univariate analysis with all demographic factors.
b All univariate p-values of ≤ 0.05 were included in the multivariate analysis, using a binomial logistic regression model.
c OR > 1.0 implies higher chance of response.
d Histologies of NSCLC included adenocarcinoma (N = 30) and squamous cell carcinoma (N = 6).
e Other tumors include adrenal carcinoma (n = 1), appendix adenocarcinoma (n = 1), basal cell carcinoma (n = 2), bladder transitional cell carcinoma (n = 4), breast
cancer (n = 3), cervical cancer (n = 2), colon adenocarcinoma (n = 5), cutaneous squamous cell carcinoma (n = 8), hepatocellular carcinoma (n = 3), head and neck
(n = 13), Merkel cell carcinoma (n = 2), ovarian carcinoma (n = 2), pleural mesothelioma (n = 1), prostate cancer (n = 1), renal cell carcinoma (n = 6), sarcoma
(n = 3), thyroid cancer (n = 3), unknown primary squamous cell carcinoma (n = 2), and urethral squamous cell carcinoma (n = 1).
f TMB low = 1–5 mutations/Mb; TMB intermediate = 6–19 mutations/Mb; TMB high ≥ 20 mutations/Mb.
g An estimate of the APOBEC-related mutagenesis was obtained for each patient using the AMSE tool, available at https://github.com/KwatME/mutational_signature.
Patients were classified in APOBEC-related mutagenesis LOW phenotype for scores ≤ 0.727 and in APOBEC-related mutagenesis HIGH phenotype for scores > 0.727.
h Other immunotherapy included OX40 (n = 2), anti-CD73 (n = 1), anti-CTLA4 (n = 2), OX40+ IDO (n = 1), anti-PD-1+ anti-CTLA4 (n = 1), and IDO+ anti-PD-1 (n = 1).
e1550341-8 A. BOICHARD ET AL.
Importantly, this analysis indicates that APOBEC signature is
correlated with higher rates of objective response to immu-
notherapy and longer PFS in patients treated with PD-1/PD-L1
checkpoint blockade. The correlation between APOBEC-related
mutagenesis and immunotherapy response was independent of
high TMB in multivariate analysis. Of interest, of the 19 patients
presenting an objective response to immunotherapy, 18 had
a high APOBEC estimate. The sensitivity of APOBEC-related
signature for response was therefore 95%; the negative predictive
value was 97%. Even so, the specificity was low (35%) since there
were patients that did not respond that had high APOBEC-
associated signature. Indeed, the combination of APOBEC-
related mutagenesis and TMB was a more effective predictor of
outcome (by model fit) than either alone. The optimized sensi-
tivity and specificity for the combination of APOBEC-related
signature and TMB was 90% and 65%. Therefore, it seems
possible to postulate that the non-responders who have high
TMB/APOBEC may have additional biomarkers that correlate
with outcome. Studies are ongoing in an expanded cohort of
patients to determine if lack of PD-L1 expression would identify
the TMB/APOBEC high tumors that do not respond to immu-
notherapy with PD-1/PD-L1 checkpoint blockade. Such
a scenario could occur, even in the presence of highly immuno-
genic APOBEC-related mutagenesis bearing tumors, if other
checkpoints were operative.
There might also be other potential complexities associated
with PD-1/PD-L1 response that depend on specific functional
characteristics of distinct cellular states and may not be easily
captured in a single mutation signature index. For instance, the
molecular differences inherent to each tumor type may lead to
conflicting conclusions. In breast cancer, Smid et al. 2016 33
showed that expression of immunotherapy predictive biomar-
kers is linked to an increase in amino acid charge but not in
amino acid hydrophobicity when the tumor is impacted by the
APOBEC-related mutation signature. Our observations may be
different because they are based on analysis of a pan-cancer
group including 30 distinct tumor types, as well as using
a different type of metric. Smid et al. 201633 refers to hydro-
phobic amino acid content increase (in percent), while we cal-
culated the overall hydrophobicity increase across the entire
coding genome (using the Kyte-Doolittle scale for
hydrophobicity34). Finally, other factors may be operative that
could moderate immunogenicity. For instance, binding of spe-
cific peptides to MHC I molecules influences presentation and
immune response35,36 and warrants investigation in the context
of APOBEC signatures.
In conclusion, both in silico computation and curation of
human cancer samples indicates that APOBEC-related muta-
genesis results in hydrophobic neo-peptides, with hydrophobi-
city being a known feature that increases immunogenicity. In
patients treated with immunotherapy, APOBEC-related signa-
ture was predictive of response and PFS and, in multivariate
analysis, the correlation with response was independent of high
TMB. The combination of TMB and APOBEC-related signature
had higher predictive value for the outcome than either alone. At
the operating point with 90% sensitivity, the combined model
had a specificity of 65%. Additionally, this study highlights the
possibility of using panel-based DNA-sequencing results (com-
monly used in clinical practice) rather than whole-genome
sequencing methods, in order to estimate the impact of
APOBEC-related signature on patient’s tumors. The use of
APOBEC-related mutagenesis estimates may represent a new
biomarker of response to immunotherapy that could be used
alone or in combination with already described criteria, in order
to improve the selection of patients that would benefit from such
agents and, therefore, merits further investigations.
Methods
In silico modeling of APOBEC-related mutagenesis
We recreated all possible 6-nucleotide stretches and, on these
stretches, we applied the APOBEC-relatedmutational signatures
(as an average of signatures 2 and 13 previously described by
ref.19, Supplemental Figure 3). The use of 6-nucleotide stretches
was chosen in order to take into consideration the three distinct
reading frames of the template for further translation. If we had
considered only 3-nucleotide stretches, we would not have been
able to determine the effects of mutations at the 1st and 3rd
positions, since APOBEC requires a leading and trailing nucleo-
tide when creating a mutation. The use of 6-nucleotide stretches
also facilitated the calculation of the amino-acid product hydro-
phobicity, as those were encoding clearly-defined dipeptides.
Using the Kyte-Doolittle hydropathy scale 34, we calculated the
hydrophobicity corresponding to the amino-acid products of all
existing 4,096 stretches, before and after in silico mutagenesis
(either with or without the reciprocal strand). The hydrophobi-
city of the products before and after mutagenesis were compared
after adjusting for the probability of observing that 6-nucleotide
stretch in the human coding genome (derived from the Kazusa’s
codon usage database37) and the probability of mutagenesis
occurring at that site 19. An example of calculation is given in
Supplementary Methods.
The method above, corresponding to the generation of
a single APOBEC-related alteration, was repeated 100-times,
in order to simulate the accumulation of alterations observed
in human tumors (estimated at 84 APOBEC-related substitu-
tion per sample, see below).
Analysis of APOBEC-related mutational signature in TCGA
pan-cancer tumor samples
Data retrieval
Mutation description and mRNA expression profiles of
human tumors were downloaded from the TCGA project,
using the Broad GDAC Firehose website (https://gdac.broad
institute.org – standardized data run 2016_01_28). All sam-
ples were available without restriction of use on April 2018.
Data used in this study respected the TCGA Human Subjects
Protection and Data Access Policies (https://cancergenome.
nih.gov/abouttcga/policies/tcga-human-subjects-data-poli
cies).
APOBEC-related mutational signature enrichment
estimation for TCGA samples
The analysis of APOBEC-related mutations was performed
using the P-MACD (Pattern of Mutagenesis by APOBEC
Cytidine Deaminases) tool.13 The results were given as
ONCOIMMUNOLOGY e1550341-9
number of mutations probably due to APOBEC. Tumors were
classified as APOBEC-mutagenesis positive if presenting at
least one alteration caused by APOBEC, and negative if not
presenting any alteration caused by APOBEC.
Hydrophobicity analysis
From 9,166 samples in the TCGA database (33 distinct tumor
types), we selected a subset of highly mutated tumors (the top
30% in mutational burden) and eliminated tumors with
POLE, POLD1, mismatch repair (MMR) genes or microsatel-
lite instability high (MSI-high) alterations (N = 469 samples
were left for study) (description of the study cohort is pre-
sented in Supplemental Table 7). Using the mutation
description available for these tumors, we then considered,
for each sample, two variables: (i) the difference in total
hydrophobicity (after versus before mutagenesis) of all exist-
ing full-length transcripts; and (ii) the difference in total
hydrophobicity (after versus before mutagenesis) of all possi-
ble 8-mer to 10-mer neo-peptides encompassing a mutation
(since MHC-I presents 8 to 10 amino acid peptides). The
calculations of both (i) and (ii) above were computed in two
ways – either not weighted by mRNA expression levels or
weighted by these levels (in order to take into consideration
whether the neo-peptides were actually expressed). All muta-
tions, regardless of their origin, where considered in the
hydrophobicity analysis of full-length transcripts and 8-mer
to 10-mer neo-peptides. The tumors harboring at least one
APOBEC-related mutation (as described by the P-MACD
method) were compared to those without.
Immune marker analysis
Expression levels of immune markers in tumors presenting an
APOBEC-related signature were compared to those not harbor-
ing an APOBEC-related signature. The mRNA expression signal
(RNAseqV2, level 3) were integrated and normalized for each
gene, per sample, using the protocol RSEM (RNA-Sequencing
by Expectation Maximization). The standard score (z-score) for
each transcript was calculated using the mean and distribution
values found in all samples of same tumor type that are diploid
for the said gene. A z-score ≥ 2 standard deviations was used as
threshold for overexpression. For each tumor, immune markers
considered were as follows: presence of a lymphocyte or mono-
cyte infiltrate determined by immunohistochemistry, CD3G
(T-cell specific marker), CD8A, CD4, MS4A1 (B-cell marker),
CD14 (monocyte marker), CD33 (macrophage marker), IL3RA
(dendritic cell marker), NCAM1 (Natural Killer cell marker),
IFNG (interferon gamma), PD-L1 and PD-L2 mRNA expres-
sion. The analysis was performed using the complete set of non-
melanoma, non-MSI/MMR/POLE/POLD1 altered tumors from
TCGA (N = 3,300 samples).
Analysis of APOBEC-related mutagenesis signature and
tumor neo-peptide features in patients receiving PD-1/
PD-L1 blockade agents
Patient selection
We reviewed the charts of 1,638 cancer patients who had
undergone next-generation sequencing (NGS) (Foundation
Medicine, Cambridge, MA) at UC San Diego Moores
Cancer Center (eligible patients starting in October 2012).
Only patients with non-melanoma malignancies and having
received at least one line of immunotherapy were considered
(N = 99). For each case, responses to therapy were assessed
based on physician notation, using the RECIST (Response
Evaluation Criteria in Solid Tumors) criteria. This study was
performed and consents were obtained in accordance with
UCSD Institutional Review Board guidelines (NCT02478931).
Next-generation sequencing and assessment of tumor
mutational burden (TMB)
Formalin-fixed paraffin-embedded (FFPE) tumor samples were
submitted for NGS to Foundation Medicine (clinical laboratory
improvement amendments (CLIA)-certified lab). The
FoundationOne® assay was used (hybrid-capture-based 315 gene-
panel exome NGS – http://www.foundationone.com/). The
methods have been previously described in.38 Average sequen-
cing depth of coverage was greater than 250X, with more than
100X for more than 99% of the exons covered. For TMB, the
number of somatic mutations detected onNGS (interrogating 1.2
mega-bases of the genome) was quantified and that value was
extrapolated to the whole exome using a validated algorithm.25,39
Alterations likely to be bona fide oncogenic drivers and germline
polymorphisms were excluded. TMB was measured in mutations
per mega-base (Mb). TMB levels were divided into three groups:
low (1–5 mutations/Mb), intermediate (6–19 mutations/Mb),
and high (≥ 20 mutations/Mb).40
APOBEC-related mutational signature enrichment
estimation for patient samples
Results from the FoundationOne® assay were used to first gen-
erate variants and then compute an APOBEC mutational signa-
ture estimate (AMSE, available at https://github.com/KwatME/
mutational_signature) for each of the 99 patient samples. Binary
Sequence Alignment/Map format (.BAM) files were processed
using the variant detection FreeBayes algorithm to generate
Variant Call Format (.VCF) files. Low quality variants (QUAL
score of less than 50 or read depth of less than 100X) were
removed. We then defined single-strand DNA-specific
APOBEC cytidine deaminase(s) signatures as designated in 13
and 19.
Details of calculations are given in Supplementary
Methods.
Validation of APOBEC mutational signature enrichment
(AMSE) method on panel-based sequencing method
To assess if the genomic regions represented in a gene-panel
assay were suitable to estimate the AMSE score of the whole
exome, we compared the computation obtained for TCGA
samples using the full exome regions versus those obtained
using the FoundationOne® panel-limited assay. The results
(Supplemental Figure 1) show that for samples with muta-
tions encompassing the same range as those in our 99 patients
(remaining after filtering based on the FoundationOne
sequencing region), the correlation (R2) of the AMSE score
considering the full exome versus the limited panel regions is
0.7225 (p-value < 0.0001).
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Clinical outcome analysis of patients receiving PD-1/PD-L1
blockade agents
Patients were divided in two groups of interest: (i) patients pre-
senting a tumor with a high load of APOBEC-related mutations
(‘APOBEC high’); and (ii) patients presenting a tumor with a low
load of APOBEC-relatedmutations (‘APOBEC low’). The optimal
threshold for APOBEC estimate was selected using the Receiver-
Operating Characteristic (ROC) curve method, evaluating the
performance of the APOBEC score to discriminate patient out-
comes. Patients were also grouped by best response: patients
having presented a complete or partial response (CR/PR) were
considered of favorable outcome, whereas patients having pre-
sented a stable or progressive disease (SD/PD) were considered of
poor outcome. Best response, progression-free survival (PFS) in
months, TMB and patient demographics were compared between
‘APOBEC high’ versus ‘APOBEC low’ patients. We also devel-
oped an exploratory probabilistic model combining TMB and
APOBEC to predict clinical response to immunotherapy without
discretization or other simplifying assumptions. We modeled the
conditional probability p(R|T,A) of response (R), defined as com-
plete response or partial response (R = 1), or stable disease or
progressive disease (R = 0), as a function of the values of TMB (T)
and AMSE score (A).41
Statistical analysis
All statistical and bioinformatics analyses were conducted by
AB and PT using SAS® University Edition software (http://
support.sas.com/software/products/university-edition/) and
GraphPad Prism® version 6.01 (http://www.graphpad.com/
scientific-software/prism/). For all analysis, two-tailed tests
were used and p-value ≤ 0.05 was considered significant.
Statistical significance for the in silico modeling results were
assessed using a Wilcoxon signed-rank test (non-parametric
paired test) for the comparison of change in total hydrophobicity
before and after APOBEC-related mutagenesis in 6-nucleotide
stretches. Change in total hydrophobicity were also calculated in
TCGA cohort samples and those with and without APOBEC-
related mutagenesis were compared; these calculations were
performed for the products of full-length transcripts as well as
for 8- to 10-mer peptides; the Mann–Whitney U-test (non-
parametric unpaired test) was used. Comparisons of lymphocyte
marker expression (defined as number of tumors presenting
a marker over-expression versus number of tumors not present-
ing a marker over-expression) between groups of interest were
assessed using a Fisher’s exact test. For the clinical study, the
Fisher’s exact test was used to assess for the univariate associa-
tion between categorical variables and the response to therapy,
defined as CR/PR and SD/PD. A logistic regression based on all
factors presenting a two-tailed p-value ≤ 0.05 in the univariate
analysis was later run to assess for the set of predictors indepen-
dently associated with the response (multivariate analysis). The
association with PFS, calculated using the Kaplan-Meier
method, was assessed using the Mantel-Cox log-rank test. For
patients who received multiple immunotherapy regimens, the
treatment with the longest PFS was chosen for analysis. Patients
were considered not evaluable for inclusion in the survival
analysis if they were lost to follow-up before their first restaging.
Patients were censored if they had not progressed or died at date
of last follow-up. The exploratory probabilistic modeling the
joint probability of TMB, APOBEC and a binary variable repre-
senting the outcome was fitted using kernel-density estimation.
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